Read

Global health update: April 23, 2025

By
Learn more about Hannah Johnson.
Hannah Johnson
Senior Program Manager, Global Policy
George W. Bush Institute
January 2007 -- A doctor consults with a mother and her children about HIV/AIDS at a clinic in Nairobi, Kenya. (Shutterstock / Joseph Sohm)

Insights from Bush Institute global health expert Hannah Johnson

On April 8, the House Appropriations’ Subcommittee on National Security, Department of State, and Related Programs hosted a hearing assessing the President’s Emergency Plan for AIDS Relief (PEPFAR). The hearing displayed the bipartisan support for PEPFAR – essential since the program’s launch in 2003 – as members from both parties, including Chairman Mario Diaz-Balart and Ranking Member Lois Frankel, applauded the 26 million lives it has saved. The hearing also showcased continued challenges that the program faces as the administration’s position on foreign assistance evolves.

The first U.S. Global AIDS Coordinator, Ambassador Mark Dybul, participated in the hearing and testified on the need to foster a structured, tailored transition for PEPFAR countries to assume ownership of the program. Members from across the aisle agreed that while a multi-year transition that enables country-led sustainability is necessary, an abrupt stop to PEPFAR programming would be counterproductive to over two decades of work, jeopardize American interests and investments, and risk millions of lives.

The George W. Bush Institute’s PEFPAR Beyond 2030 series recommends a tiered approach to PEPFAR transition. Countries are in different phases of ending HIV as a public health threat by 2030. While some are on the path to self-sustainability, others are falling behind. It is possible, even necessary, to begin to transition PEPFAR programming to country ownership, which would require less funding as the program nears 2030. But an abrupt halt in funding in two years or less could prevent PEPFAR from achieving its goals.

It is crucial to think carefully and at the country-specific level about this transition to ensure that our strategic goals are achieved. Our rivals like China and Russia are waiting in the wings to influence, overtake, and denigrate decades-long U.S. efforts. We must continue to support PEPFAR and ensure we get the job done – America’s geopolitical influence and precious lives are at risk.

Bush Institute Insights

In the Bush Institute’s PEPFAR Beyond 2030 series, we present three case studies that demonstrate the degrees of progress that countries have made towards HIV testing and treatment. While countries like Botswana and Zambia are impressively reaching their 95-95-95 targets, countries like Ghana and the Philippines are lagging behind.

Policymakers, PEPFAR, and program implementers should learn from these case studies to develop data-driven programming that will ensure countries end or are close to ending HIV as a public health threat by 2030. While some countries are ready to move forward, other countries will require more focus to keep their populations healthy and to prevent regression in the fight against HIV/AIDS.

Figure of the week

300%

That’s the increase in U.S. exports to Africa since the launch of PEPFAR. According to a recent study in The Lancet, PEPFAR has led to substantial collateral benefits, in addition to the 26 million lives it has saved. In 2024 alone, the U.S. exported $32.1 billion in goods to Africa, up from $6.9 billion in 2001. Other collateral benefits include increased employment, decreased orphanhood, and a reduction in forced migration.

Ally updates

UNAIDS continues to provide country-specific updates on the impact of the funding freeze on PEPFAR programming:

  • In Malawi, facilities that provide pediatric HIV treatment and early infant diagnosis are operating at reduced capacity. HIV diagnostic assistants are no longer available, limiting HIV testing at public facilities.
  • In Lesotho, there have been disruptions to HIV testing services, including point-of-care machines. Significant staffing shortages have led to overcrowding at facilities across the country.
  • Angolan facilities are suffering from low stocks of HIV commodities as a result of logistical disruptions. Community-led monitoring – one of the most influential methods for ensuring people living with HIV continue their treatment – has also stopped in Angola, as PEPFAR funding for this work has been terminated.
  • In Laos, 50% of U.S. funding to maternal and child health programs has been cut. As a result, healthcare provider training and plans for maternal and pediatric point-of-care sites have been reduced. Community-led organizations across Laos have also been reduced or suspended, limiting their capacity to collect and report data.

In the news

  • Dr. Jonathan Ellen, pediatrician, epidemiologist, public healthresearcher, and former hospital CEO, penned an op-ed for the National Review calling on President Donald Trump to preserve PEPFAR, arguing that the program is “a strategic investment in global stability.” In the piece, Ellen emphasized PEPFAR’s crucial impact in fighting diseases and its groundbreaking commitment to sustainability and country ownership. Following the article’s release, Ellen sat down with the National Review’s Kathryn Jean Lopez to discuss how there is no program more pro-life than PEPFAR.
  • In a letter published in The Lancet, 11 African health leaders expressed deep gratitude to the U.S. for the support received through PEPFAR and pledged to take the lead in the next chapter of the fight against HIV: “Together we look forward to accelerating our progress over the next 5 years, as we transition these life-saving HIV programs – supported by PEPFAR – into the care of our governments, institutions, faith-based and community-based organizations, and the communities we serve between 2025 and 2030.”
  • In Think Global Health, missionary surgeon Beth Stuebing details the aftermath of PEPFAR and USAID funding cuts in Malawi, where 10% of the population is HIV positive. Drawing on firsthand experience, Stuebing highlights the staff and supply shortages that have crippled the country’s response to the AIDS epidemic. She also warns of the growing threat of drug-resistant HIV strains spreading beyond Africa.